Dobber Jos, Latour Corine, van Meijel Berno, Ter Riet Gerben, Barkhof Emile, Peters Ron, Scholte Op Reimer Wilma, de Haan Lieuwe
ACHIEVE Centre of Applied Research, Faculty of Health, Amsterdam University of Applied Sciences, Amsterdam, Netherlands.
Research Group Mental Health Nursing, Inholland University of Applied Sciences, Amsterdam, Netherlands.
Front Psychiatry. 2020 Mar 24;11:78. doi: 10.3389/fpsyt.2020.00078. eCollection 2020.
Trials studying Motivational Interviewing (MI) to improve medication adherence in patients with schizophrenia showed mixed results. Moreover, it is unknown which active MI-ingredients are associated with mechanisms of change in patients with schizophrenia. To enhance the effect of MI for patients with schizophrenia, we studied MI's active ingredients and its working mechanisms.
First, based on MI literature, we developed a model of potential active ingredients and mechanisms of change of MI in patients with schizophrenia. We used this model in a qualitative multiple case study to analyze the application of the active ingredients and the occurrence of mechanisms of change. We studied the cases of fourteen patients with schizophrenia who participated in a study on the effect of MI on medication adherence. Second, we used the Generalized Sequential Querier (GSEQ 5.1) to perform a sequential analysis of the MI-conversations aiming to assess the transitional probabilities between therapist use of MI-techniques and subsequent patient reactions in terms of change talk and sustain talk.
We found the therapist factor "a trusting relationship and empathy" important to enable sufficient depth in the conversation to allow for the opportunity of triggering mechanisms of change. The most important conversational techniques we observed that shape the hypothesized active ingredients are reflections and questions addressing medication adherent behavior or intentions, which approximately 70% of the time was followed by "patient change talk". Surprisingly, sequential MI-consistent therapist behavior like "affirmation" and "emphasizing control" was only about 6% of the time followed by patient change talk. If the active ingredients were embedded in more comprehensive MI-strategies they had more impact on the mechanisms of change.
Mechanisms of change mostly occurred after an interaction of active ingredients contributed by both therapist and patient. Our model of active ingredients and mechanisms of change enabled us to see "MI at work" in the MI-sessions under study, and this model may help practitioners to shape their MI-strategies to a potentially more effective MI.
研究动机性访谈(MI)以提高精神分裂症患者药物依从性的试验结果不一。此外,尚不清楚MI的哪些有效成分与精神分裂症患者的改变机制相关。为增强MI对精神分裂症患者的疗效,我们研究了MI的有效成分及其作用机制。
首先,基于MI相关文献,我们构建了一个关于MI在精神分裂症患者中的潜在有效成分及改变机制的模型。我们在一项定性多案例研究中使用该模型,以分析有效成分的应用及改变机制的发生情况。我们研究了14名参与MI对药物依从性影响研究的精神分裂症患者的案例。其次,我们使用广义序列查询器(GSEQ 5.1)对MI对话进行序列分析,旨在评估治疗师使用MI技术与患者随后在改变谈话和维持谈话方面的反应之间的过渡概率。
我们发现治疗师因素“信任关系和同理心”对于使对话有足够深度以创造触发改变机制的机会很重要。我们观察到,塑造假设有效成分的最重要对话技术是针对药物依从行为或意图的反映和提问,约70%的情况下随后会出现“患者改变谈话”。令人惊讶的是,与MI一致的序列治疗师行为,如“肯定”和“强调控制”,只有约6%的情况下随后会出现患者改变谈话。如果有效成分嵌入更全面的MI策略中,它们对改变机制的影响更大。
改变机制大多发生在治疗师和患者双方贡献的有效成分相互作用之后。我们的有效成分和改变机制模型使我们能够在研究的MI会话中看到“起作用的MI”,该模型可能有助于从业者将他们的MI策略塑造为潜在更有效的MI。